Full-Time

Director – KOL Management & Engagement

Central

Posted on 9/26/2023

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Senior

San Francisco, CA, USA + 1 more

More locations: Remote in USA

Category
Growth & Marketing
Required Skills
Sales
Management
Branding/Brand Strategy
Marketing
Data Analysis

You match the following BridgeBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 7+ years of industry experience (sales/marketing, clinical practice, academic, and/or medical affairs)
  • Field-based experience is preferred but not required
  • Cardiovascular experience is preferred but not required
  • Experience leading KOL engagement activities, including the management of KOL data and implementation of strategic initiatives
  • High-level strategic thinking, with the ability to translate customer insights into actionable marketing strategy and to align with critical stakeholders on operational priorities
  • Proven self-starter, able to work independently and as part of a team
  • Able to handle full workload across multiple projects
  • Collaborates seamlessly across functions to build effective working relationships and align on strategy and execution
  • Proven track record of solid strategic leadership, teamwork, innovation, and project management and demonstrated ability to manage, lead, and mentor individuals
  • Successful launch experience in a competitive market preferred
  • Excellent oral, written, and presentation skills
  • High level of self-awareness and understanding of the importance of self-monitoring behavior for continuous improvement
  • True entrepreneurial spirit – BridgeBio was built to do things differently and address the needs of underserved populations, driven by science and unrelenting passion for patients
  • 30-40% travel anticipated for conference attendance, KOL meetings, speaker program attendance, etc. (expected to be on the higher end, 40%+, during initial launch preparation)
Responsibilities
  • Design KOL identification/profiling, mapping, and critical strategic efforts to establish engagement with and by KOLs in the cardiology space
  • Lead the creation, execution, and maintenance of the commercial Key Opinion Leader engagement plan to build, cultivate and maintain KOL relationships
  • Develop resources for KOL engagement activities, such as a database or similar platform for tracking KOL partnership
  • Collaborate to develop and manage the Acoramidis speaker bureau, inclusive of program structure/development/maintenance, speaker selection, and innovative approaches to further brand messaging
  • Lead U.S. Congress KOL engagement planning
  • Partner closely with internal teams to ensure we are using appropriate insights and metrics to inform the KOL management strategy and activities – directly to KOLs and with KOLs toward community physicians
  • Lead the development and execution of commercial advisory boards to inform, uncover opportunities and support brand strategy and launch preparation
  • Liaise and communicate with internal stakeholders, including medical affairs and product development, and advisory board insights to ensure aligned understanding and implementation
  • Proactively evaluate/assess the relevant market landscape, monitoring changes in market dynamics, competition, clinician needs, and practices
  • Developing targeted measurement plans – setting goals and meeting KPIs
  • Work cross-functionally with agency partners, sales, commercial operations, brand analytics, I.T., MCM, etc.
Desired Qualifications
  • Successful launch experience in a competitive market
  • High level of self-awareness and understanding of the importance of self-monitoring behavior for continuous improvement
  • True entrepreneurial spirit
  • 30-40% travel anticipated for conference attendance, KOL meetings, speaker program attendance, etc.

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

1%

2 year growth

0%
The Manila Times
Jan 8th, 2025
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

Access Market Intelligence
Dec 6th, 2024
Orsini and PANTHERx Rare Selected by BridgeBio as Pharmacy Partners for ATTRUBY

PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, also announced that it was selected by BridgeBio for the distribution of Attruby (acoramidis).

PR Newswire
Nov 26th, 2024
Bridgebio Selects Pantherx® Rare Specialty Pharmacy For Distribution Of Attruby™ (Acoramidis)

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attruby™ (acoramidis), a high-affinity transthyretin (TTR) stabilizer for twice daily oral administration, approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).2,5. Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring "rescue mutation" of the TTR gene (T119M) that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes. "Panther is committed to providing tailored solutions for people living with rare and devastating conditions and we look forward to the partnership with BridgeBio and serving the needs of patients suffering from transthyretin amyloid cardiomyopathy," said Rob Snyder, Executive Chair, PANTHERx® Rare Pharmacy

MarketBeat
Nov 24th, 2024
Jennison Associates LLC Invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Jennison Associates LLC invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Business Wire
Sep 9th, 2024
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage precision oncology company, has announced the appointment of Yong (Ben) Ben, MD, as Chief Medical and Development Officer.

INACTIVE